Lexicon Pharmaceuticals, Inc. (LXRX) Valuation

Valuation

Model-based estimates, not advice. The DCF is the discounted-cash-flow value per share; compare it with the price, not as a target.

DCF fair value

-701.5%

-$8.66

vs $1.44 price

Levered DCF

-$15.60

After debt service

Piotroski score

2 / 9

Weak

Altman Z-score

-6.05

Distress zone

Rating

D+

Overall 1 / 5

Ratios by fiscal year

Margins and yields are shares of revenue, equity or price; multiples are ×.

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
P/E	-8.21×	-1.17×	-1.91×	-3.08×	-6.46×	-5.43×	3.37×	-5.82×
P/B	3.88×	1.62×	3.63×	2.7×	5.05×	2.42×	3.76×	-0.48×
P/S	8.38×	7.6×	281×	2,277.34×	1,925.73×	15.8×	1.37×	11.11×
EV / EBITDA	-10.76×	-1.51×	-2.49×	-3.25×	-5.91×	-6.46×	4.39×	-8.19×
Gross margin	99.4%	98.0%	-4798.0%	-37681.3%	-18371.8%	92.0%	99.0%	96.1%
Operating margin	-98.2%	-634.2%	-14265.0%	-72489.2%	-29224.8%	-199.2%	43.9%	-163.4%
Net margin	-101.1%	-644.8%	-14710.9%	-73341.0%	-29449.0%	-244.1%	40.4%	-190.7%
Current ratio	4.88×	5.44×	5.6×	6.08×	4.02×	3.37×	5.17×	4.72×
Debt / equity	0.58×	0.74×	1.14×	0.47×	0.02×	0.08×	2.11×	-0.17×
Interest coverage	-5.87×	-12.65×	-13.11×	-36.24×	-108.59×	-3.29×	6.84×	-4.97×
Dividend yield	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Payout ratio	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%

Key metrics by fiscal year

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
Return on equity	-46.8%	-137.3%	-190.2%	-87.0%	-77.3%	-37.5%	111.1%	8.2%
Return on invested capital	-28.7%	-77.5%	-86.2%	-58.4%	-75.2%	-28.3%	38.9%	-44.3%
Return on assets	-27.2%	-67.2%	-77.2%	-52.5%	-64.1%	-28.7%	31.2%	-42.4%
Free cash flow yield	-16.3%	-76.1%	-48.0%	-28.5%	-15.4%	-37.7%	25.8%	-21.2%
Earnings yield	-12.1%	-84.8%	-52.4%	-32.2%	-15.3%	-15.5%	29.5%	-17.2%
Enterprise value	$445.4M	$278.1M	$421.9M	$325.5M	$512.1M	$265.6M	$651.5M	$787.1M
Net debt / EBITDA	-0.67×	-0.23×	-0.49×	-0.09×	0.71×	2.76×	1.42×	-0.88×
Cash conversion cycle (days)	-3,715	-8,592	219	1	-44	-1,029	-832	-1,046